Cardiogen vs Serrapeptase
A side-by-side research comparison of Cardiogen and Serrapeptase across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardiogen | Serrapeptase |
|---|---|---|
| Full name | Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator) | Serrapeptase (Serratiopeptidase) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research compound (peptide bioregulator) | Dietary supplement |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance. | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. |
| Molecular weight | ~460 Da | ~52,000 Da |
| Half-life | Short (peptide) | ~4-6 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | Oral (enteric-coated required); detectable in bloodstream |
| Typical dose | ~1-2 capsules/day or short injectable courses | 120,000-240,000 SPU |
| Frequency | Once daily | Daily on empty stomach |
| Route | Oral capsule or subcutaneous | Oral (enteric-coated) |
Cardiogen reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Related comparisons
Research and educational reference only. Not medical advice.